Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery

Product Highlight

Mouse anti-M13 phage coat protein g8p

Antibodies recognising M13 filamentous phage coat proteins are instrumental in the selection and detection of phages expressing specific antibody fragments or peptide sequences at their surface. The monoclonal antibodies manufactured and supplied by Exalpha react with either the pIII (g3p) or pVIII (g8p) proteins of M13 filamentous bacteriophage. All antibodies are available in a purified format. The antibodies are fully validated and are suitable for a wide range of techniques including:

  • ELISA
  • Flow Cytometry
  • Western Blot
  • Immunohistochemistry
  • Immunoprecipitation
For more information, click here for our M13 Bacteriophage information page.

News

Two more of our excellent products have been published by PubMed:

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Borazanci, E., et al., J. Gastrointest. Oncol., 8, 164-172 (2017)
Using Exalpha SPARC Antibody (Cat. No. X1867P)

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Steen, N.V., et al., Am. J. Cancer Res., 7, 816-830 (2017)
Using Exalpha's FITC labeled anti PY20 Antibody (Cat. No. X1017)

Exalpha Biologicals, Inc.

Cytokeratin 13

  • Product Code: X1735M
  • Size: 100 µg
  • Availability: In Stock In Stock
  • Price (USD): $335

Cat #

X1735M		 Quantity:      

Data Sheet

Product Name

Cytokeratin 13

Host/Source

Mouse

Clone

1C7

Isotype

IgG2a

Product Type

Monoclonal Antibody

Reactivity

Human

Applications

Western Blot, Immunohistochemistry

Purification

Protein A/G Chromatography

Size

100 µg

Price (USD)

$335

Background

Cytokeratins are a subfamily of intermediate filament proteins and are characterized by a remarkable biochemical diversity, represented in human epithelial tissues by at least 20 different polypeptides. They range in molecular weight between 40 kDa and 68 kDa and isoelectric pH between 4.9 – 7.8. The individual human cytokeratins are numbered 1 to 20. The various epithelia in the human body usually express cytokeratins which are not only characteristic of the type of epithelium, but also related to the degree of maturation or differentiation within an epithelium. Cytokeratin subtype expression patterns are used to an increasing extent in the distinction of different types of epithelial malignancies. The cytokeratin antibodies are not only of assistance in the differential diagnosis of tumors using immunohistochemistry on tissue sections, but are also a useful tool in cytopathology and flow cytometric assays.

Immunogen

Hybridoma produced by the fusion of splenocytes from BALB/c mice immunized with cytokeratin preparation extracted from human esophagus and mouse SP2/0 myeloma cells.

Positive Control

This antibody reacts exclusively with cytokeratin 13 which is present in non-cornified squamous epithelia, except cornea, and transitional epithelial regions, with the exception of basal cell layers of some stratified epithelia.

Formulation

Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Database Links:

SwissProtP13646Human

References

1. van Muijen, G. N., et al. (1986). Cell type heterogeneity of cytokeratin expression in complex epithelia and carcinomas as demonstrated by monoclonal antibodies specific for cytokeratins nos. 4 and 13, Exp Cell Res 162, 97-113.
2. Weikel, W., et al. (1987). Characterization of subcolumnar reserve cells and other epithelia of human uterine cervix. Demonstration of diverse cytokeratin polypeptides in
reserve cells, Virchows Arch B Cell Pathol Incl Mol Pathol 54, 98-110.
3. Smedts, F., et al. (1990). Changing patterns of keratin expression during progression of cervical intraepithelial neoplasia, Am J Pathol 136, 657-68.
4. van Niekerk, C. C., et al. (1991). Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas, Am J Pathol 138, 455-63.
5. Smedts, F., et al. (1992). Keratin expression in cervical cancer, Am J Pathol 141, 497-511.
6. Bauwens, L. J., et al. (1992). Expression of intermediate filament proteins in the adult human vestibular labyrinth, Ann Otol Rhinol Laryngol 101, 479-86.
7. Van Niekerk, C. C., et al. (1993). Changes in expression of differentiation markers between normal ovarian cells and derived tumors, Am J Pathol 142, 157-77.
8. van Dorst, E. B., et al. (1998). The limited difference between keratin patterns of squamous cell carcinomas and adenocarcinomas is explicable by both cell lineage and state of differentiation of tumour cells, J Clin Pathol 51, 679-84.